COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.

Dr. Miller will also join a panel of gene therapy experts for a discussion on “Dosing & Redosing in Gene Therapy,” October 14 at 11:00 a.m. PT.

The conference will take place October 12-14, 2021, at the Park Hyatt Aviara, in Carlsbad, California. To learn more about the event and registration, please visit: https://meetingonthemesa.com.

Forge will be taking meetings during Meeting on the Mesa. Please contact John Maslowski, Chief Commercial Officer, at CD@forgebiologics.com if you are interested in connecting and learning more about how Forge’s manufacturing solutions can support your gene therapy program.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005142/en/